Paper: A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Fedratinib vs. Best Available Therapy in Myelofibrosis Patients Treated Previous with Ruxolitinib

Read the full article here

Related Articles